164 related articles for article (PubMed ID: 34617578)
1. Expression of epithelial membrane protein (EMP) 1, EMP 2, and EMP 3 in thyroid cancer.
Kim EK; Koo JS
Histol Histopathol; 2022 Jan; 37(1):51-61. PubMed ID: 34617578
[TBL] [Abstract][Full Text] [Related]
2. Expression of Autophagy-Related Proteins in Different Types of Thyroid Cancer.
Kim HM; Kim ES; Koo JS
Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28257096
[TBL] [Abstract][Full Text] [Related]
3. Expression of EMP1, EMP2, and EMP3 in breast phyllodes tumors.
Cha YJ; Koo JS
PLoS One; 2020; 15(8):e0238466. PubMed ID: 32857809
[TBL] [Abstract][Full Text] [Related]
4. Expression of serine/glycine metabolism-related proteins is different according to the thyroid cancer subtype.
Sun WY; Kim HM; Jung WH; Koo JS
J Transl Med; 2016 Jun; 14(1):168. PubMed ID: 27277113
[TBL] [Abstract][Full Text] [Related]
5. EMP1, EMP 2, and EMP3 as novel therapeutic targets in human cancer.
Wang YW; Cheng HL; Ding YR; Chou LH; Chow NH
Biochim Biophys Acta Rev Cancer; 2017 Aug; 1868(1):199-211. PubMed ID: 28408326
[TBL] [Abstract][Full Text] [Related]
6. BRAF V600E mutation in papillary thyroid carcinoma: significant association with node metastases and extra thyroidal invasion.
Chakraborty A; Narkar A; Mukhopadhyaya R; Kane S; D'Cruz A; Rajan MG
Endocr Pathol; 2012 Jun; 23(2):83-93. PubMed ID: 22105775
[TBL] [Abstract][Full Text] [Related]
7. BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma.
Costa AM; Herrero A; Fresno MF; Heymann J; Alvarez JA; Cameselle-Teijeiro J; García-Rostán G
Clin Endocrinol (Oxf); 2008 Apr; 68(4):618-34. PubMed ID: 18070147
[TBL] [Abstract][Full Text] [Related]
8. Follicular variant of papillary thyroid carcinoma with B-type Raf(V600E) showing higher frequency of suspicious sonographic features and multifocality.
Shin DY; Kim KJ; Chang S; Kim H; Hwang S; Kim W; Bae J; Park S; Kang SW; Chung WY; Lee EJ
Head Neck; 2015 Nov; 37(11):1590-5. PubMed ID: 24909403
[TBL] [Abstract][Full Text] [Related]
9. Follicular histotypes of oncocytic thyroid carcinomas do not carry mutations of the BRAF hot-spot.
Musholt PB; Musholt TJ; Morgenstern SC; Worm K; Sheu SY; Schmid KW
World J Surg; 2008 May; 32(5):722-8. PubMed ID: 18235983
[TBL] [Abstract][Full Text] [Related]
10. Expression and Role of Epithelial Membrane Proteins in Tumorigenesis of Hormone Receptor-Positive Breast Cancer.
Cha YJ; Koo JS
J Breast Cancer; 2020 Aug; 23(4):385-397. PubMed ID: 32908789
[TBL] [Abstract][Full Text] [Related]
11. Specific immunohistochemical detection of the BRAF V600E mutation in primary and metastatic papillary thyroid carcinoma.
Zhu X; Luo Y; Bai Q; Lu Y; Lu Y; Wu L; Zhou X
Exp Mol Pathol; 2016 Feb; 100(1):236-41. PubMed ID: 26795218
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of
Kim H; Kim BH; Kim YK; Kim JM; Oh SY; Kim EH; Lee MJ; Kim JH; Jeon YK; Kim SS; Lee BJ; Kim YK; Kim IJ
J Korean Med Sci; 2018 Jul; 33(27):e75. PubMed ID: 29962924
[TBL] [Abstract][Full Text] [Related]
13. BRAF(V600E) Mutation is Associated with Decreased Disease-Free Survival in Papillary Thyroid Cancer.
Fraser S; Go C; Aniss A; Sidhu S; Delbridge L; Learoyd D; Clifton-Bligh R; Tacon L; Tsang V; Robinson B; Gill AJ; Sywak M
World J Surg; 2016 Jul; 40(7):1618-24. PubMed ID: 27138882
[TBL] [Abstract][Full Text] [Related]
14. How Many Papillae in Conventional Papillary Carcinoma? A Clinical Evidence-Based Pathology Study of 235 Unifocal Encapsulated Papillary Thyroid Carcinomas, with Emphasis on the Diagnosis of Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features.
Xu B; Serrette R; Tuttle RM; Alzumaili B; Ganly I; Katabi N; Tallini G; Ghossein R
Thyroid; 2019 Dec; 29(12):1792-1803. PubMed ID: 31452453
[No Abstract] [Full Text] [Related]
15. [Follicular cell (papillary and follicular) thyroid carcinoma, genetic inheritance, and molecular diagnostic markers].
Kazubskaia TP; Kozlova VM; Kondrat'eva TT; Pavlovskaia AI; Marakhonov AV; Baranova AV; Ivanova NI; Stepanova AA; Poliakov AV; Belev NF; Brzhezovskiĭ VZh
Arkh Patol; 2014; 76(5):3-12. PubMed ID: 25543402
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathologic features and BRAF(V600E) mutation analysis in cutaneous metastases from well-differentiated thyroid carcinomas.
Erickson LA; Jin L; Nakamura N; Bridges AG; Markovic SN; Lloyd RV
Cancer; 2007 May; 109(10):1965-71. PubMed ID: 17387744
[TBL] [Abstract][Full Text] [Related]
17. BRAF
Kaabouch M; Chahdi H; Azouzi N; Oukabli M; Rharrassi I; Boudhas A; Jaddi H; Ababou M; Dakka N; Boichard A; Bakri Y; Dupuy C; Al Bouzidi A; El Hassani RA
Afr Health Sci; 2020 Dec; 20(4):1849-1856. PubMed ID: 34394248
[TBL] [Abstract][Full Text] [Related]
18. BRAF
Shi C; Cao J; Shi T; Liang M; Ding C; Lv Y; Zhang W; Li C; Gao W; Wu G; Man J
World J Surg Oncol; 2020 Jun; 18(1):145. PubMed ID: 32593310
[TBL] [Abstract][Full Text] [Related]
19. Epidermal growth factor receptor overexpression is a marker for adverse pathologic features in papillary thyroid carcinoma.
Fisher KE; Jani JC; Fisher SB; Foulks C; Hill CE; Weber CJ; Cohen C; Sharma J
J Surg Res; 2013 Nov; 185(1):217-24. PubMed ID: 23746767
[TBL] [Abstract][Full Text] [Related]
20. Association between diffuse lymphocytic infiltration and papillary thyroid cancer aggressiveness according to the presence of thyroid peroxidase antibody and BRAF
Lee YK; Park KH; Park SH; Kim KJ; Shin DY; Nam KH; Chung WY; Lee EJ
Head Neck; 2018 Oct; 40(10):2271-2279. PubMed ID: 29935011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]